OR WAIT null SECS
The company has manufactured double-digit number of batches on the new filling line, for use in early-stage clinical trials.
On Dec. 13, 2016, Vetter announced that its new clinical syringe line has manufactured double-digit number of batches for use in early-stage clinical trials. The line is part a growth expansion at the company’s Skokie facility. This expansion includes an increase in storage capability designed to manage the continued growth in syringe fills and larger batch sizes. This storage expansion includes six new chest freezers, two upright freezers, and two refrigerator units. The company expects storage will be expanded by the end of the year to increase capacity by 150%. Vetter has also launched an aseptic syringe filling line.
Vetter’s Skokie facility is the company’s US clinical manufacturing site, providing development support for preclinical through Phase II injectables, primarily complex biologics. The facility, currently operating with a staff of more than 60, offers chemical analysis and microbiology labs, material preparation, and compounding functions. The facility includes cleanrooms, visual inspection capabilities, and GMP storage.